Skip to main content
DCGO logo

DCGO · DocGo Inc.

Track DCGO — free
$0.18 -0.01 (-4.20%) At close · Nov 18
Market Cap
$17.37M
Shares
98.99M
Volume · Nov 18 555.8K Avg daily vol (3M) 773.15K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.18 Open$0.18 Day$0.18–0.20 52W close$0.18–1.08 Avg vol 30d737K Short int2.1M · 2.2% of shares · 3.9d Short vol26% Last earningsNov 9, 2026 DataDec 2020–Nov 2026 Filing10-Q · Nov 9

Up next

Mar 15, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 13
Current report 8-K
Lee Bienstock receives conditional $785,000 severance

DocGo Inc. agreed November 13, 2026: Lee Bienstock will depart March 31, 2027, unless extended or earlier terminated. He remains CEO until a successor starts, then serves as senior advisor; transition pay is $90,000 monthly and conditional severance is $785,000.

Director or officer change, or executive pay Read from the first part of this long document
5 source passages
This TRANSITION SERVICES AND SEPARATION AGREEMENT (this “Agreement”) is entered into by and between DocGo Inc., a Delaware corporation (the “Company”), and Lee Bienstock (“Executive”). On November 13, 2026, the Company and Mr. Bienstock entered into a Transition Services and Separation Agreement (the “Transition Agreement”), pursuant to which Mr. Bienstock will continue to serve as the Company’s Chief Executive Officer (“CEO”) and provide assistance in transitioning the role from January 1, 2027 through March 31, 2027, or such later date as may mutually be agreed by the parties (the “Transition Period”). If a successor CEO commences employment prior to March 31, 2027 (the “Separation Date”), Mr. Bienstock will continue to serve as a senior advisor to the board and the successor CEO through the Separation Date. As consideration for his continued service during the Transition Period and subject to the terms of the Transition Agreement, Mr. Bienstock is entitled to the following: (i) a salary of $90,000 per month Subject to Mr. Bienstock’s execution of a general release and waiver of claims and the terms of the Transition Agreement, and in accordance with the severance benefits of his current employment agreement, Mr. Bienstock is also entitled to the following: a severance payment of $785,000 (the “Severance Payment”) Open the document at this passage
Nov 9
Earnings call
CEO transition announced as revenue guidance is lowered

DCGO announced CEO Lee Bienstock will transition out and remain through at least March 31, 2027. Full-year 2026 revenue guidance fell to approximately $300 million, while adjusted EBITDA loss guidance stayed at $17 million to $22 million.

6 source passages
Earnings Call Transcript - DCGO Q3 FY2026 Lee Bienstock, CEO Today, we announced that I'll be transitioning out of my role as CEO of .go upon the appointment of my successor I plan to stay on until at least March 31, 2027 We now expect full-year 2026 revenue of approximately $300 million We continue to anticipate a full-year adjusted EBITDA loss of between $17 million and $22 million. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Third-quarter revenue rises 3.7% as net loss narrows to $18.3 million

For the three months ended September 30, 2026, DocGo reported revenues of $73.4 million, up 3.7%, and a net loss of $18.3 million versus $29.7 million for the three months ended September 30, 2025.

Read from the MD&A section
3 source passages
For the three months ended September 30, 2026, total revenues were $73.4 million, an increase of $2.6 million, or 3.7%, compared to the three months ended September 30, 2025. For the three months ended September 30, 2026, the Company recorded a net loss of $18.3 million, compared to a net loss of $29.7 million for the three months ended September 30, 2025. DocGo anticipates that fuel prices will moderate slightly Open the document at this passage
Nov 9
Current report 8-K
Revenue rises as CEO search begins

DocGo reported revenue of $73.4 million, up from $70.8 million, and net income of ($18.1) million. Full-year 2026 revenue guidance fell to approximately $300 million from $305-$310 million; adjusted EBITDA guidance remained ($17-$22) million, and a CEO search began.

Financial results
5 source passages
Total revenue for the third quarter of 2026 was $73.4 million, compared to $70.8 million in the third quarter of 2025. Net income for the third quarter of 2026 was ($18.1) million, compared to net income of ($29.7) million in the third quarter of 2025. Full-year 2026 revenue is expected to be approximately $300 million, compared to the Company’s prior guidance of $305-$310 million. The revision is due to the ongoing elimination and restructuring of unprofitable business lines. Full-year 2026 adjusted EBITDA2 is expected to be ($17-$22) million, unchanged from last quarter. Additionally, the Company announced that the Board has begun a comprehensive search to identify the next CEO, as Mr. Bienstock’s employment contract expires on December 31, 2026. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$297.34M
Trailing 12 months
Net income (TTM)
−$181.25M
Trailing 12 months
Revenue growth YoY
+3.7%
Year over year
Operating margin
-53.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-174.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$18.91M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.2%
Year over year · more shares
Price change (1Y)
-81.1%
Trailing year
Short interest
2.2%
Latest settlement · 3.9 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 9, 2026
Q3 FY26

TL;DR. DocGo returned to year-over-year revenue growth, improved gross margin and adjusted SG&A, and expects positive EBITDA in 2027. However, revenue guidance was reduced, cash fell to $19.1 million, mobile-health margin and care-in-the-home volume declined, fuel costs remained a headwind, and a CEO transition introduces execution risk.

Bullish
  • + Q3 revenue was $73.4 million versus $70.8 million a year earlier, marking the company's first year-over-year revenue increase since Q2 2023.
  • + Adjusted EBITDA loss narrowed to $3.2 million from $7.2 million in Q3 2025.
  • + Gross margin improved to 33.3% from 30.5% in Q2.
  • + Medical transportation revenue rose to $53.3 million from $50.1 million in Q3 2025 and reached a quarterly record.
  • + Adjusted SG&A declined to $28.7 million from $29.7 million in Q2 and $30.8 million in Q1.
  • + Management anticipates positive EBITDA for full-year 2027.
Bearish
  • − Full-year 2026 revenue guidance was reduced to approximately $300 million from $305 million to $310 million.
  • − Unrestricted cash declined to $19.1 million at September 30 from $25.2 million at June 30.
  • − Mobile health adjusted gross margin fell to 29.7% from 36.2% in Q3 2025.
  • − Care-in-the-home visit volume declined 26% year over year after outreach and clinical operations were deliberately reduced.
  • − Higher fuel costs restrained transportation gross margin by about 52 basis points and consolidated gross margin by about 38 basis points versus the prior year.
  • − The board has initiated a CEO search as Lee Bienstock's employment contract approaches expiration, creating leadership-transition and execution risk.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −67%
below
Price vs 50-day avg −42%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −34%
trailing
6-month return −73%
trailing
YTD return −80%
this year
Relative strength −70%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-28% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.15% of shares out · ▲ +7.9% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
86 holders — near 3-yr low, contrarian setup
Squeeze score 48
elevated · 0–100
Fundamentals
Strong
Revenue growth −48%
Y/Y
EPS growth −1122%
Y/Y
Free cash flow $29.9M
Buyback $62.0M
authorized
Balance sheet $50.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 88%
annualized · 1-yr
Max drawdown −84%
past year
ATR 15.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the Earnings Call filed Nov 9, 2026
full year 2026
Full year 2026 revenue Lowered $300M
Aug 17, 2026 $305M – $310M changed to Nov 9, 2026 $300M
prior FY $322.2M midpoint −6.9% Y/Y
for the year
Medical transportation revenue $205M – $210M
Remote patient monitoring revenue $16M – $17M
Previous outlook earlier release · from the Earnings Call filed Aug 17, 2026

Still-open targets the latest release did not restate under the same label.

Adjusted EBITDA loss · full-year $17M – $22M
Guided vs delivered · last 4 settled
Full-year 2025 revenue Full-year 2025
guided $315M – $320M
$322.2M Beat +1.5%
Revenue Full-year 2024
guided $600M – $650M
$616.56M In line
Full-year 2023 revenue guidance Full-year 2023
guided $615M – $625M
$624.29M In line
Revenue guidance Fiscal 2022
guided $430M – $440M
$440.52M Beat +1.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−67% Bearish
Price vs 50-day avg
−42% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Distributing
-28% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.15% of shares out · ▲ +7.9% MoM · 3.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
86 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $1
vs 200-day avg -67% vs 50-day avg -42%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted gross margin non-GAAP 31.8% nine months ended September 30, 2026 —
Adjusted gross profit non-GAAP $70,751,737 nine months ended September 30, 2026 —
medical transportation gross margins 34.7% the third quarter —
Average trip price $426 the three months ended June 30, 2026 filing —
Hicuity trailing 12-month adjusted EBITDA non-GAAP 4.5M trailing 12-month basis —
Hicuity trailing 12-month revenue 65M trailing 12-month basis —
U.S. trip volumes 80,447 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DCGO
DocGo Inc.
this stock
$17.37M -80.0% -47.7% — 2.2%
HCA
HCA Healthcare, Inc.
$99.51B +2.0% +7.1% 15.8 2.3%
FSNUY
Fresenius SE & Co. KGaA
$33.07B +2.4% — — 0.0%
THC
Tenet Healthcare Corp
$21.60B +36.5% +0.9% 7.9 2.2%
EHC
Encompass Health Corp
$13.24B +27.1% +10.5% 21.1 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
86
% held
30.6%
Net QoQ
-8.0M sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
29
View
Short & Settlement
Short Interest Rising
Shares short
2.1M
Days to cover
3.9d
Change
+155.7K sh
View
Short Volume
Short vol %
26%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
19.7K
Value
$5.3K
As of
Oct 22, 2026
View
Off-Exchange
Off-exchange %
67.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$322.2M
Net income (FY)
$-182.4M
EPS diluted
$-1.84
View
Buybacks
Authorized · 2 programs
$62.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 13, 2026
This year
22

DocGo Inc. agreed November 13, 2026: Lee Bienstock will depart March 31, 2027, unless extended or earlier terminated. He remains CEO until a successor starts, then serves as senior advisor; transition pay is $90,000 monthly and conditional severance is $785,000.

View
Proposed Sales
Value
$15.4K
Shares
16.9K
Filed
Dec 15, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
DocGo Announces Third Quarter 202…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
DCGO -24.3% -33.9% -73.3% -28.9% -80.0%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -20.4% -28.4% -69.9% -25.5% -87.1%

Capital returns

Buyback programs · 2 active · as of Aug 5, 2024
Authorized (total)
$62.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1822359 CUSIP 256086109 13F (30d) 95 filings 82 filers Visit website Investor relations